Matches in SemOpenAlex for { <https://semopenalex.org/work/W2106975939> ?p ?o ?g. }
- W2106975939 abstract "The introduction of tyrosine kinase inhibitor (TKI) therapy has markedly reduced the use of allogeneic (allo) hematopoietic stem cell transplantation (HSCT), which is no longer standard practice in the first chronic phase in chronic myelogenous leukemia and is currently reserved after failure of TKI or in advanced phase of disease. We compared the outcome of Philadelphia chromosome-positive (Ph+) leukemia patients who received a first allo-HSCT in our center in both the pre-TKI era and the TKI era. The primary end point was to compare the 2 groups' overall survival (OS), leukemia-free survival (LFS), cumulative incidence of nonrelapse mortality, and relapse incidence. The secondary end point was to underline in the TKI era the impact of the pretransplantation minimal residual disease (MRD) on the outcomes. A total of 69 patients with Ph+ leukemia were included and their outcomes analyzed. For the purpose of this analysis, we defined 2 groups: group A (n = 39) included patients treated in the pre-TKI era, treated from January 1989 until December 2001, and group B (n = 30) included patients treated in the TKI era, treated from January 2002 until December 2013. Additional analysis was performed in group B for whom detailed TKIs and MRD data were collected. The study took place in our cancer center in the department of HSCT, Villejuif, France. The median follow-up duration for group A was 116.1 months (range, 1.1 to 240.1 months) and for group B was 8.3 months (range, 3.5 to 141.7 months). At 3 years, the LFS and OS were higher in group B (respectively, 66% and 71%) than in group A (respectively, 63% and 57%) (P > .05). The LFS and OS at 3 years of the pretransplantation MRD-negative (< 0.01%) patients were significantly (P < .05) higher (respectively, 83% and 94%) than the pretransplantation MRD-positive patients (respectively, 43% and 46%). Our data, although statistically not significant, suggest better outcomes for Ph+ leukemia patients undergoing allo-HSCT in the TKI era. Mostly TKI does not adversely affect the transplantation outcomes and can be used successfully as a bridge to allo-HSCT, especially in advanced disease. In addition, we highlight the importance of obtaining deep pretransplantation MRD negativity." @default.
- W2106975939 created "2016-06-24" @default.
- W2106975939 creator A5017435311 @default.
- W2106975939 creator A5028073020 @default.
- W2106975939 creator A5040092926 @default.
- W2106975939 creator A5081937285 @default.
- W2106975939 date "2015-06-01" @default.
- W2106975939 modified "2023-09-27" @default.
- W2106975939 title "Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome–Positive Leukemia: 25 Years' Experience at Gustave Roussy Cancer Campus" @default.
- W2106975939 cites W1491993932 @default.
- W2106975939 cites W1604668557 @default.
- W2106975939 cites W1605230984 @default.
- W2106975939 cites W1973617793 @default.
- W2106975939 cites W1978194079 @default.
- W2106975939 cites W1979300931 @default.
- W2106975939 cites W1981154777 @default.
- W2106975939 cites W1984166296 @default.
- W2106975939 cites W1985640974 @default.
- W2106975939 cites W1987374204 @default.
- W2106975939 cites W1987891242 @default.
- W2106975939 cites W1998593414 @default.
- W2106975939 cites W2011474502 @default.
- W2106975939 cites W2014467271 @default.
- W2106975939 cites W2018699937 @default.
- W2106975939 cites W2021334577 @default.
- W2106975939 cites W2033862877 @default.
- W2106975939 cites W2036724262 @default.
- W2106975939 cites W2036862498 @default.
- W2106975939 cites W2041353685 @default.
- W2106975939 cites W2076372887 @default.
- W2106975939 cites W2076405958 @default.
- W2106975939 cites W2079962671 @default.
- W2106975939 cites W2084452268 @default.
- W2106975939 cites W2087090648 @default.
- W2106975939 cites W2089360398 @default.
- W2106975939 cites W2090896574 @default.
- W2106975939 cites W2105400883 @default.
- W2106975939 cites W2108322312 @default.
- W2106975939 cites W2118796952 @default.
- W2106975939 cites W2131067167 @default.
- W2106975939 cites W2135492799 @default.
- W2106975939 cites W2160811827 @default.
- W2106975939 cites W2161605543 @default.
- W2106975939 cites W2163594056 @default.
- W2106975939 cites W2164168439 @default.
- W2106975939 cites W2288682663 @default.
- W2106975939 cites W2290614159 @default.
- W2106975939 cites W2292226371 @default.
- W2106975939 cites W2312804644 @default.
- W2106975939 cites W2412777037 @default.
- W2106975939 cites W2799244951 @default.
- W2106975939 cites W3191903670 @default.
- W2106975939 cites W3044574244 @default.
- W2106975939 doi "https://doi.org/10.1016/j.clml.2015.05.001" @default.
- W2106975939 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26297265" @default.
- W2106975939 hasPublicationYear "2015" @default.
- W2106975939 type Work @default.
- W2106975939 sameAs 2106975939 @default.
- W2106975939 citedByCount "2" @default.
- W2106975939 countsByYear W21069759392019 @default.
- W2106975939 countsByYear W21069759392020 @default.
- W2106975939 crossrefType "journal-article" @default.
- W2106975939 hasAuthorship W2106975939A5017435311 @default.
- W2106975939 hasAuthorship W2106975939A5028073020 @default.
- W2106975939 hasAuthorship W2106975939A5040092926 @default.
- W2106975939 hasAuthorship W2106975939A5081937285 @default.
- W2106975939 hasConcept C104317684 @default.
- W2106975939 hasConcept C120665830 @default.
- W2106975939 hasConcept C121332964 @default.
- W2106975939 hasConcept C121608353 @default.
- W2106975939 hasConcept C126322002 @default.
- W2106975939 hasConcept C138626823 @default.
- W2106975939 hasConcept C143998085 @default.
- W2106975939 hasConcept C167135981 @default.
- W2106975939 hasConcept C185592680 @default.
- W2106975939 hasConcept C2776960273 @default.
- W2106975939 hasConcept C2777408962 @default.
- W2106975939 hasConcept C2778461978 @default.
- W2106975939 hasConcept C2778904597 @default.
- W2106975939 hasConcept C2911091166 @default.
- W2106975939 hasConcept C55493867 @default.
- W2106975939 hasConcept C61511704 @default.
- W2106975939 hasConcept C71924100 @default.
- W2106975939 hasConcept C88879693 @default.
- W2106975939 hasConceptScore W2106975939C104317684 @default.
- W2106975939 hasConceptScore W2106975939C120665830 @default.
- W2106975939 hasConceptScore W2106975939C121332964 @default.
- W2106975939 hasConceptScore W2106975939C121608353 @default.
- W2106975939 hasConceptScore W2106975939C126322002 @default.
- W2106975939 hasConceptScore W2106975939C138626823 @default.
- W2106975939 hasConceptScore W2106975939C143998085 @default.
- W2106975939 hasConceptScore W2106975939C167135981 @default.
- W2106975939 hasConceptScore W2106975939C185592680 @default.
- W2106975939 hasConceptScore W2106975939C2776960273 @default.
- W2106975939 hasConceptScore W2106975939C2777408962 @default.
- W2106975939 hasConceptScore W2106975939C2778461978 @default.
- W2106975939 hasConceptScore W2106975939C2778904597 @default.
- W2106975939 hasConceptScore W2106975939C2911091166 @default.
- W2106975939 hasConceptScore W2106975939C55493867 @default.
- W2106975939 hasConceptScore W2106975939C61511704 @default.